Sign In
Buy LGND
$287.54
-8.75 (-2.95%)
At Close: Jul 31, 2026
Alliancebernstein L.P. Has $7.08 Million Stock Holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND)
08:54am, Wednesday, 08'th Apr 2020
Alliancebernstein L.P. lessened its holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission.
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Reiterated by HC Wainwright
07:52am, Wednesday, 08'th Apr 2020
Ligand Pharmaceuticals (NASDAQ:LGND)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Monday, AnalystRatings.com reports. They presently have a $237.00 targe
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $229
12:00am, Wednesday, 08'th Apr 2020Should You Take Comfort From Insider Transactions At Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)?
04:16pm, Tuesday, 07'th Apr 2020
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference
11:30am, Tuesday, 07'th Apr 2020
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced tha
H.C. Wainwright says Captisol a 'key focus' for Ligand, reiterates Buy LGND
02:40pm, Monday, 06'th Apr 2020
H.C. Wainwright says Captisol a 'key focus' for Ligand, reiterates Buy H.C. Wainwright LGND
H.C. Wainwright Reiterates Their Buy Rating on Ligand Pharma (LGND)
02:23pm, Monday, 06'th Apr 2020
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND) today and set a price target of $237.00. The company's shares
H.C. Wainwright Reiterates Their Buy Rating on Ligand Pharma (LGND)
02:22pm, Monday, 06'th Apr 2020
H.C. Wainwright analyst
Joseph Pantginis
reiterated a
Buy
rating on Ligand Pharma (
LGND
–
Research Report
) today and set a price target of
$237.00
. The company’s shares closed last Monday at $7
Ligand Provides a Corporate Update and Announces May 6th as the Date for First Quarter Earnings Call
11:00am, Monday, 06'th Apr 2020
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provides a general corporate update, as follows:
Mason Street Advisors LLC Sells 628 Shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND)
10:06am, Sunday, 05'th Apr 2020
Mason Street Advisors LLC trimmed its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Com
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Shares Sold by Advisors Asset Management Inc.
08:28am, Friday, 03'rd Apr 2020
Advisors Asset Management Inc. reduced its holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 13.6% during the 4th quarter, Holdings Channel reports. The firm owned 5,448 shares of the biotechno
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs and Ion Channel Technologies
08:02pm, Thursday, 02'nd Apr 2020
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations. As previously announced, the purchase price w
Advisor Group Inc. Has $154,000 Holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND)
08:06am, Thursday, 02'nd Apr 2020
Advisor Group Inc. lessened its holdings in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 31.7% during the fourth quarter, according to the company in its most recent filing with the Securiti
Global Immune Checkpoint Inhibitors Market Outlook 2022
06:15pm, Wednesday, 01'st Apr 2020
The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
